Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline in Chronic Migraine
NCT05525611Completed
- Sponsor
- Aarhus University
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of cabergoline in chronic migraine (2 arms), sponsored by Aarhus University. Primary endpoint: Change in days with headache at 12 weeks. Started Sep 2022; status: completed.
02
Drugs
cabergoline
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT05525611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525611.